Journal of Clinical Pharmacy and Therapeutics · 2022 · 12 citations · 12 references
MedicineOrthopaedic SurgeryOrthopedic SurgeryOrthopedicsPain ManagementPain MedicineAnalgesiaNon-opioid AnalgesicsNonopioid AnalgesicsOpioid AnalgesicsOpioid TherapyPostoperative PainAnalgesic Efficacy AssessmentComparative Analgesic EfficacyHip Surgery AnalgesiaNonopioid AnalgesiaPharmacological Pain ReliefPostoperative Opioid AnalgesiaPreoperative AnalgesiaPreoperative Pain Management
WHAT IS KNOWN AND OBJECTIVE: Postoperative pain relief is a critical issue for hip arthroscopy surgery (HAS). This study aimed to investigate the effect of preemptive non-steroidal anti-inflammatory drugs (NSAIDs) for postoperative analgesia in femoroacetabular impingement (FAI) patients receiving HAS. METHODS: This multicenter, randomized, controlled study enrolled 204 FAI patients receiving HAS, then assigned them to preoperative (PRE, N = 103) or postoperative (POS, N = 101) group as a 1:1 ratio; the PRE group administrated NSAIDs from 24 h pre-surgery to day 7 (D7) post-surgery, while the POS group administrated NSAIDs from 12 h post-surgery to D7 post-surgery. RESULTS AND DISCUSSION: Pain at rest was reduced at D1 (p = 0.016) and D2 (p = 0.023); pain at movement was decreased at D1 (p = 0.002), D2 (p = 0.020), and D3 (p = 0.030) in the PRE group compared with POS group, but not at other time points (all p > 0.05). Patient's satisfaction was increased at D1 (p = 0.013) and D3 (p = 0.029) in the PRE group compared to the POS group, but not at D7 (p = 0.145). Pethidine was less consumed at D3 (p = 0.038) and D7 (p = 0.017) in the PRE group in contrast with the POS group. Harris hip scores were similar at D7 (p = 0.124), month 1 (M1) (p = 0.273), and M3 (p = 0.360) between groups. Adverse events incidence was similar between groups (all p > 0.05). Besides, subgroup analysis discovered that pain was not influenced by the types of NSAID in both groups (all p > 0.05). WHAT IS NEW AND CONCLUSION: Starting NSAIDs before HAS provides better short-term pain relief and improves patient's satisfaction compared with its postoperative utilization, while does not induce additional adverse events in FAI patients.
12
Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect.
Xiaohong Chen, Jinye Bai, Fang Shen et al. · PubMed · 2004 · 42 citations
Robert W. Westermann, Jennifer Hu, Mia S. Hagen et al. · Arthroscopy The Journal of Arthroscopic and Related Surgery · 2018 · 26 citations
Holly D. Aitken, Robert W. Westermann, Nicholas I. Bartschat et al. · Journal of Orthopaedic Research® · 2022 · 25 citations · Full text